![](/img/cover-not-exists.png)
Survival advantage of exemestane (EXE, Aromasin®) over megestrol acetate (MA) in postmenopausal women with advanced breast cancer (ABC) refractory to tamoxifen (TAM): results of a phase III randomized double-blind study
E. Bajetta, L.Y. Dirix, L.E. Fein, S.E. Jones, J. Cervek, M. Kaufmann, C. Fowst, A. Polli, E. di Salle, G. MassiminiVolume:
35
Year:
1999
Language:
english
DOI:
10.1016/s0959-8049(99)80705-9
File:
PDF, 110 KB
english, 1999